The Women’s Health Research Unit is conducting a study to evaluate the safety and effectiveness of a new investigational medication, Linzagolix, for pain in women with endometriosis.
Endometriosis is the presence and growth of tissue normally found inside the lining of the uterus, but growing outside the uterus and causing symptoms such as painful menstruation, non-menstrual pelvic pain and/or painful sexual intercourse. Linzagolix (the study drug) is being investigated as a possible new medication option for the management of pain associated with endometriosis. The purpose of the study is to look at Linzagolix (the study drug) using 3 randomly assigned study treatment groups. One group will receive a placebo (a pill that looks like the study drug but has not medication in it). The study will take up to 15 months to complete.
You may be eligible if you:
- Women between the ages of 18-49 years of age
- Currently pre-menopausal (before menopause)
- Have a diagnosis of Endometriosis
- Have moderate to severe pain related to Endometriosis
- Additional eligibility criteria will be reviewed during early screening to determine eligibility to participate in this study.
Qualified participants receive all study-related medical exams and laboratory services at no charge, and will be compensated $2050 for time and travel.
Who do I contact for additional information?
To find out more information and to learn if you are qualified to participate, please call the Women's Health Research Unit confidential recruitment line at 503-494-3666 or email us at email@example.com.